Charles River Labs stock tumbles as FDA shifts from animal testing

Investing.com -- Shares of Charles River Labs (NYSE: NYSE:CRL) plummeted by 28% following the announcement from the U.S. Food and Drug Administration (FDA) that it plans to phase out the requirement for animal testing in the development of monoclonal antibodies and other drugs. This groundbreaking decision is anticipated to significantly impact the traditional business model of companies like Charles River Labs, which provides preclinical laboratory services, including animal testing for drug development.

The FDA's new approach aims to replace animal testing with more effective, human-relevant methods, such as AI-based computational models and lab-grown human organoids. This shift is expected to improve drug safety, accelerate the evaluation process, and reduce both research and development costs and ultimately, drug prices. The implementation of these New Approach Methodologies (NAMs) will commence immediately for investigational new drug applications.

The agency's decision is in response to the need for more human-relevant testing methods and is seen as a win-win for public health and ethics. According to FDA Commissioner Martin A. Makary, M.D., M.P.H., this initiative marks a paradigm shift in drug evaluation that promises to accelerate treatments while reducing animal use. The FDA will also begin to use pre-existing real-world safety data from other countries with comparable regulatory standards to make efficacy determinations.

The market's reaction to the FDA's announcement reflects concerns over the future revenue and growth prospects for Charles River Labs. The company's stock has taken a significant hit as investors reassess the impact of the potential reduction in demand for animal testing services, which have been a core part of the company's offerings.

The FDA's roadmap outlines regulatory incentives for companies that submit strong safety data from non-animal tests, which may include streamlined review processes. This policy change is expected to encourage investment in modernized testing platforms, potentially leading to faster drug development timelines without compromising safety.

Charles River Labs and other companies in the preclinical laboratory services industry may now face the challenge of adapting to these regulatory changes and the evolving landscape of drug development. As the FDA continues to promote the adoption of innovative, humane testing methods, the impact on traditional animal testing providers is likely to be profound.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.